Company intelligence / Profile preview

Emerald Health Sciences

Long Beach, California, USAnewswire.ca ↗

Ownership: Private
Development stage: Other

Overview

Emerald Health Sciences is primarily a biotechnology investment and holding company with interests in cannabinoid-based drug development through subsidiaries such as Emerald Health Pharmaceuticals and formerly Emerald Health Therapeutics. Its affiliates have advanced novel small molecules targeting neurodegenerative and autoimmune disorders into early clinical stages. The most advanced programs are in Phase 2 for chronic limb-threatening ischemia and preclinical for other CNS/immune indications.

Therapeutic areas: Rare DiseasesNeurologyOphthalmologyGastroenterologyEndocrinologyImmunologyRheumatology
Modalities: Small moleculeChemical drugs
Industry: Biotech

Partnerships

NextPharmaPurisys

Beyond the preview

Go deeper on Emerald Health Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Emerald Health Sciences.

Explore the full profile